Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention

American Heart Journal

Volumn 137, Issue 2, 1999, Pages 250-257

  Ragosta, Michael ^a   Karve, Milind ^b   Brezynski, Damien ^b   Humphries, John ^b   Sanders, John M ^b   Sarembock, Ian J ^b   Gimple, Lawrence W ^b   Powers, Eric R ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOPEPTIDE A; HEPARIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ANGIOGRAPHY; ARTERY DISSECTION; ARTICLE; ATHERECTOMY; BLOOD CLOTTING TIME; CORONARY ARTERY DISEASE; CORONARY SINUS; DRUG EFFICACY; FEMALE; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOGENESIS; THROMBUS;

EID: 0032931855     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1999.v137.91541     Document Type: Article

References (24)

1. 1. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty. Clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-35.
2. 2. Wilcox JN. Thrombin and other potential mechanisms underlying restenosis. Circulation 1991;84:432-5.
3. 3. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisted: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284-93.
4. 4. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79:657-65.
5. 5. Heras M, Chesebro JH, Webster MWI, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82:1476-84.
6. 6. Manolis AS, Manolis HM, Stefanadis C, Toutouzas P. Plasma level changes of fibrinopeptide A after uncomplicated coronary angioplasty. Clin Cardiol 1993;16:548-52.
7. 7. Marmur JD, Merlini PA, Sharma SK, et al. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 1994;24:1484-91.
8. 8. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996; 94:2064-71.
9. 9. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
10. 10. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343:881-6.
11. 11. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation 1995;91:2151-7.
12. 12. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996;78(suppl 3A):35-40.
13. 13. Ferguson JJ. EPILOG and CAPTURE trials halted because of positive interim results. Circulation 1996;93:637.
14. 14. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333:764-9.
15. 15. Serruys PW, Herrman JPR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-63.
16. 16. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty. Circulation 1988; 78:486-502.
17. 17. Gasperetti CM, Gonias SL, Gimple LW, Powers ER. Platelet activiation during coronary angioplasty in humans. Circulation 1993; 88:2728-34.
18. 18. Detre KM, Holmes DR, Holubkov R, et al. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-50.
19. 19. Gasperetti CM, Feldman MD, Burwell LR, Angello DA, Haugh KH, Owen RM, et al. Influence of contrast media on thrombin formation during angioplasty. J Am Coll Cardiol 1991;18:443-50.
20. 20. Grines CL, Schreiber TL, Savas V, Jones DE, Zidar FJ, Gangadharan V, et al. A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary ongioplasty. J Am Coll Cardiol 1996;27:1381-6.
21. 21. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
22. 22. Barry WL, Gimple LW, Humphries JE, et al. Arterial thrombin activity after angioplasty in an atherosclerotic rabbit model. Time course and effect of hirudin. Circulation 1996;94:88-93.
23. 23. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina. Circulation 1989;80:17-23.
24. 24. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Circulation 1990;82:1193-202.